Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2015



Summary



GlobalData's clinical trial report, “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2015" provides data on the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope


- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)



Reasons to buy


- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Introduction 6
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Sanofi 30
Clinical Trial Overview of Sanofi 30
Nuo Therapeutics, Inc. 31
Clinical Trial Overview of Nuo Therapeutics, Inc. 31
ZonMw 32
Clinical Trial Overview of ZonMw 32
PTC Therapeutics, Inc. 33
Clinical Trial Overview of PTC Therapeutics, Inc. 33
Parkway Pantai Limited 34
Clinical Trial Overview of Parkway Pantai Limited 34
Multiplex Pharma Holdings LLC 35
Clinical Trial Overview of Multiplex Pharma Holdings LLC 35
Fate Therapeutics, Inc. 36
Clinical Trial Overview of Fate Therapeutics, Inc. 36
ArmaGen Technologies, Inc. 37
Clinical Trial Overview of ArmaGen Technologies, Inc. 37
Clinical Trial Overview of Top Institutes / Government 38
Masonic Cancer Center 38
Clinical Trial Overview of Masonic Cancer Center 38
Los Angeles Biomedical Research Institute 39
Clinical Trial Overview of Los Angeles Biomedical Research Institute 39
University of California, Los Angeles 40
Clinical Trial Overview of University of California, Los Angeles 40
Erasmus MC 41
Clinical Trial Overview of Erasmus MC 41
University of Texas Southwestern Medical Center at Dallas 42
Clinical Trial Overview of University of Texas Southwestern Medical Center at Dallas 42
University of Chicago 43
Clinical Trial Overview of University of Chicago 43
University Hospital Hamburg-Eppendorf 44
Clinical Trial Overview of University Hospital Hamburg-Eppendorf 44
University of Louisville 45
Clinical Trial Overview of University of Louisville 45
Emory University 46
Clinical Trial Overview of Emory University 46
University of Minnesota 47
Clinical Trial Overview of University of Minnesota 47
Five Key Clinical Profiles 48
Appendix 81
Abbreviations 81
Definitions 81
Research Methodology 82
Secondary Research 82
About GlobalData 83
Contact Us 83
Disclaimer 83
Source 83

List of Tables

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Region, 2015* 7
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 15
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 18
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Terminated Clinical Trials, 2015* 24
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2015* 30
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nuo Therapeutics, Inc., 2015* 31
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by ZonMw, 2015* 32
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by PTC Therapeutics, Inc., 2015* 33
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Parkway Pantai Limited, 2015* 34
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Multiplex Pharma Holdings LLC, 2015* 35
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fate Therapeutics, Inc., 2015* 36
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by ArmaGen Technologies, Inc., 2015* 37
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2015* 38
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Los Angeles Biomedical Research Institute, 2015* 39
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2015* 40
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2015* 41
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas Southwestern Medical Center at Dallas, 2015* 42
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Chicago, 2015* 43
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Hamburg-Eppendorf, 2015* 44
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Louisville, 2015* 45
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2015* 46
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2015* 47

List of Figures

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 15
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 18
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 82

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Global CRO Market : Transformation, Developments, Opportunities and Future of CRO Market

Global CRO Market : Transformation, Developments, Opportunities and Future of CRO Market

  • $ 10 000
  • Industry report
  • February 2015
  • by Frost & Sullivan

Key Findings •The global Contract Research Organization (CRO) market was $ x billion in 2014 and is expected to reach $ x billion in 2019, growing at a robust CAGR (2014-2019) of x %. •The penetration ...

Proteomics: Technologies and Global Markets

Proteomics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • February 2015
  • by BCC Research

REPORT HIGHLIGHTS The global proteomics market was valued at nearly $5.1 billion in 2014 and is growing at a compound annual growth rate (CAGR) of 18.0% to reach a forecast value of $11.6 billion by 2019. ...

Drug Discovery Technologies, BCC Research

Drug Discovery Technologies, BCC Research

  • $ 6 650
  • Industry report
  • February 2015
  • by BCC Research

REPORT HIGHLIGHTS The global market for drug discovery technologies reached nearly $39.5 billion and $46.5 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.